Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
OTCMKTS:MKGAF

Merck KGaA Earnings Date & Estimates

Merck KGaA logo
$167.21 +9.24 (+5.85%)
As of 10/20/2026 03:55 PM Eastern

Merck KGaA is estimated to report earnings on Thursday, November 12, 2026, before market opens.

Research:Profile

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Merck KGaA

Merck KGaA is expected to post earnings of $2.37 per share on revenue of $6.13 billion.

Consensus Estimates

Consensus EPS
$2.37
Expected Revenue
$6.13 billion

Recent Track Record

Last Reported
Q2 2024
Last Quarter EPS
$1.51
Last Quarter Revenue
$5.76 billion

Prepare for the Earnings Call

Merck KGaA Earnings FAQ

Merck KGaA (OTCMKTS:MKGAF) is estimated to report earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Merck KGaA to post earnings of $2.37 per share for the quarter.

The consensus revenue estimate for Merck KGaA is $6.13 billion for the quarter.

Merck KGaA Earnings Headlines

Silence Therapeutics: Downgrade To Hold On Merck KGaA Acquisition And PV siRNA
October 19 at 5:29 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4955316-silence-therapeutics-downgrade-to-hold-on-merck-kgaa-acquisition-and-pv-sirna
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
October 19 at 8:48 AM  |  wsj.comhttps://www.wsj.com/tech/biotech/germanys-merck-to-buy-u-k-biotech-silence-therapeutics-for-1-3-billion-aab773c5
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.tc pixel
 |  Decentralized Masters (Ad)
Merck KGaA (OTCMKTS:MKGAF) Shares Gap Down - Time to Sell?
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31111480
Medicare drug pricing model to affect only four firms after Trump’s MFN policy
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/medicare-drug-pricing-model-to-affect-only-four-firms-after-trump-s-mfn-policy/ar-AA2dpFvL
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
July 29, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260728223289/en/evinova-launches-strategic-partnership-with-merck-kgaa-darmstadt-germany-to-define-the-future-of-clinical-development/
See More Merck KGaA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merck KGaA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merck KGaA and other key companies, straight to your email.

About Merck KGaA

Merck KGaA (OTCMKTS:MKGAF) is a German science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The company operates under the name EMD Serono in the United States and Canada, where the Merck name is associated with a separate company.

Merck KGaA operates through three primary business sectors: Healthcare, Life Science and Electronics. Its Healthcare business develops and markets prescription medicines, including treatments in oncology, neurology and immunology, as well as fertility and other specialty-care products. The Life Science business supplies laboratory products, equipment, services and technologies used in pharmaceutical manufacturing, biotechnology, research and academic laboratories.

The Electronics business develops materials and solutions for the semiconductor and display industries, including specialty chemicals, semiconductor materials and liquid-crystal technologies. Merck KGaA serves customers in markets around the world through research, manufacturing and commercial operations across multiple regions. Belén Garijo has served as the company’s chief executive officer and chair of its executive board since 2021.

View Merck KGaA Profile
Earnings Tools